Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CEO Bruce C. Cozadd sold 500 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $107.90, for a total value of $53,950.00. Following the transaction, the chief executive officer now owns 438,473 shares of the company's stock, valued at approximately $47,311,236.70. The trade was a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jazz Pharmaceuticals Stock Up 1.8%
Jazz Pharmaceuticals stock traded up $1.97 during mid-day trading on Friday, hitting $110.77. 266,164 shares of the company's stock were exchanged, compared to its average volume of 835,734. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06. The stock has a 50 day moving average of $108.37 and a two-hundred day moving average of $121.04. The stock has a market cap of $6.83 billion, a P/E ratio of 15.61, a P/E/G ratio of 1.04 and a beta of 0.33. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.
Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The firm's revenue for the quarter was down .5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.68 earnings per share. As a group, analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages recently issued reports on JAZZ. Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday. Morgan Stanley lowered their price target on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Robert W. Baird decreased their target price on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Finally, Piper Sandler reissued an "overweight" rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $184.00.
Check Out Our Latest Stock Analysis on Jazz Pharmaceuticals
Institutional Investors Weigh In On Jazz Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the business. IFP Advisors Inc acquired a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $25,000. Hurley Capital LLC bought a new stake in Jazz Pharmaceuticals during the 1st quarter worth approximately $25,000. Quadrant Capital Group LLC boosted its stake in Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP grew its holdings in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. Finally, CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 89.14% of the company's stock.
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Further Reading
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
